The European Myeloma Network
A non-profit organisation created to increase understanding of multiple myeloma and to produce effective research projects and clinical trials.
Read more
EMN2027 – Würzburg – 8-10 April, 2027
Development
Measurable residual disease (MRD)
The most widely used tests are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests use samples of bone marrow cells (taken by aspiration) and/or peripheral blood cells (taken through a vein).
About the HARMONY Alliance
Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.
The HARMONY Alliance is a Public-Private Partnership for Big Data in Hematology including over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Various groups participate in HARMONY, including EMN. HARMONY Research Project Leads and Key Opinion Leaders in Multiple Myeloma are Prof. Pieter Sonneveld, Prof. Mario Boccadoro, and Prof. Jesus San-Miguel.
About EMN
Multiple Myeloma
Multiple myeloma is a rare and highly heterogeneous hematologic
malignancy, and the clinical research certainly plays a fundamental role in
the management of patients with this disease.
To deal with such a complex scenario, in 2005, a group of European
hematologists pulled together to increase their understanding of multiple
myeloma and to produce effective research projects and clinical trials.
These efforts resulted in the creation of the European Myeloma Network
(EMN), a non profit organization.
EMN Guideline Team
Various reviews, guidelines and recommendation papers are produced under the EMN umbrella. To collect & better coordinate the various proposals and manuscripts, a guideline team is in place: Monika Engelhardt from Germany, Niels van de Donk from the Netherlands, Francesca Gay from Italy and Evangelos Terpos from Greece.
Hear from the EMN President
Diversity and inclusion
Inclusion is a major value for the EMN, particularly when it comes to clinical trials. The myeloma community is in fact highly heterogeneous and the EMN strongly believes that the same high-quality treatments should be offered to any patients, regardless of their gender, race, ethnicity, sexualorientation, disability, religion, age, cultural backgrounds, life experiences, thoughts, and ideas. We are extremely grateful for the fundamental role our patients play in the EMN clinical studies, and the contribution of each one of them is equally recognized and appreciated.
Pieter Sonneveld
President
Mario Boccadoro
Vicepresident
Fredrik Schjesvold
Director
Gordon Cook
Director
Heinz Ludwig
Director
Hermann Einsele
Director
Meletios Dimopoulos
Director
Roman Hajek
Director
Meral Beksac
Director
Christoph Driessen
Director
Xavier Leleu
Director
Marivi Mateos
Director
Evangelos Terpos
Director
Andrew Spencer
Director
Sonja Zweegman
Director
Annemiek Broijl
Core Team
Cyrille Touzeau
Core Team
Enrique Ocio
Core Team
Francesca Gay
Core Team
Guldane Cengiz Seval
Core Team
Jakub Radocha
Core Team
Leo Rasche
Core Team
Maria Gavriatopoulou
Core Team
Maria Krauth
Core Team
Rakesh Popat
Core Team
Tobias Slordahl
Core Team
Contact
To propose a study to be run in collaboration with EMN, please complete the Trial Proposal form and send it to us at: secretariat@emn.org
For more general information, you can contact us at: info@emn.life
Although we do understand sometimes it is hard to navigate the complex world of multiple myeloma, we cannot provide clinical assessments or consultations by email. Please refer to your treating physicians for any doubts, they certainly have a more complete overview of your medical history and treatments to appropriately assist you.
@EMN_EuMMnet
https://www.linkedin.com/company/emn-research-italy/
